Novo Nordisk to Pay Up to $2 Billion for Rights to Experimental Obesity and Diabetes Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
Novo Nordisk secures license to weight-loss drug candidate from China's United Labs
China-based United Laboratories International said on Monday it will license its weight-loss drug candidate to Danish ...
Novo Nordisk strikes $2 billion deal with a Chinese company making a GLP-1 drug
Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...
NBC Los Angeles5h
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Novo Nordisk to Pay Up to $2 Billion to License Chinese Company’s Weight-Loss Drug
Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...
Irish Examiner on MSN11h
Weight loss drug Wegovy set to be made available in Ireland
The European Medicines Agency (EMA) has advised that the drug can be used together with diet and physical activity to help ...
Germany’s SAP Overtakes Wegovy Maker Novo Nordisk as Europe’s Most Valuable Company
The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...
YourLifeChoices8h
Australians pay up to $2,000 a year for Ozempic—should the PBS cover it?
In the quest for health and wellness, Australians are constantly on the lookout for effective weight loss strategies. For ...